Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
December 16, 2025

Quizartinib / vanflyta for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia as of October 2024

MARA Rating Company December 16, 2025

Ranibizumab / lucentis for the treatment of age-related macular degeneration as of May 2024

MARA Rating Company December 16, 2025

Ranibizumab for treating visual impairment due to diabetic macular oedema as of October 2023

MARA Rating Company December 16, 2025

Ranibizumab / lucentis for treating visual impairment caused by macular oedema secondary to retinal vein occlusion as of May 2024

MARA Rating Company December 16, 2025

Pembrolizumab / keytruda for adjuvant treatment of resected stage 2B or 2C melanoma as of October 2022

MARA Rating Company December 16, 2025

Pembrolizumab / keytruda for neoadjuvant and adjuvant treatment of triplenegative early or locally advanced breast cancer as of December 2022

MARA Rating Company December 16, 2025

Pembrolizumab / keytruda for treating advanced or recurrent endometrial cancer as of June 2023

MARA Rating Company December 16, 2025

Pembrolizumab / keytruda for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency as of September 2023

MARA Rating Company December 16, 2025

Keytruda / pembrolizumab for treating persistent, recurrent or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS ³ 1 as of December 2023

MARA Rating Company December 16, 2025

Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over as of May 2024

MARA Rating Company December 16, 2025